Stc.unm

Eliseo F Castillo

Vojo P Deretic

Larry A Sklar

Steven Bradfute

In one embodiment, the invention provides a method of treating a subject suffering from ainfection by administering to the subject a therapeutically-effective amount of a degradative autophagy agonist or a secretory autophagy antagonist. In another embodiment, the invention provides a method of treating a subject suffering from one or more diseases selected from the group consisting of ainfection, an inflammatory disorder, an immune disorder, a cancer and a neurodegenerative disorder by administering to the subject a therapeutically-effective amount of a TBK-1 antagonist (e.g. BX795 or amlexanox). Related pharmaceutical compositions, diagnostic and screening assays and kits are also provided.

Treatment of autophagy-based disorders and related pharmaceutical compositions, diagnostic and screening assays and kits

The invention provides methods of treating autophagy mediated diseases and disorders and related pharmaceutical compositions, diagnostics, screening techniques and kits. In one embodiment, the invention provides a method of determining whether a subject suffers from, or is at risk of developing, and autophagy mediated disease state and/or condition by evaluating LC3 levels.

Growing community of inventors

Albuquerque, NM, United States of America

Eliseo F Castillo